NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced today that it has received a notification letter from Nasdaq confirming the company has regained compliance with the Minimum Bid Price Requirement under Nasdaq Marketplace Rule 5550(a)(2), closing the matter.
The company, based in Eden Prairie, Minnesota, had previously been notified on May 6, 2025, that its common stock had fallen below the $1 per share minimum bid price required for continued listing on the Nasdaq Capital Market. Nasdaq granted NeuroOne a 180-day extension on November 4, 2025, extending the compliance deadline to May 4, 2026.
To meet the requirement, NeuroOne effected a 1-for-6 reverse stock split that became effective at 5:00 p.m. Eastern Time on April 15, 2026. The company's common stock began trading on a split-adjusted basis at market open on April 16, 2026, under the same ticker symbol "NMTC" but with a new CUSIP Number, 64130M308.
This compliance milestone is critical for NeuroOne and its shareholders. Continued listing on Nasdaq ensures the company maintains access to capital markets, liquidity for investors, and the credibility associated with a major exchange listing. Failure to regain compliance could have resulted in delisting, which often leads to reduced stock liquidity, decreased investor confidence, and potential difficulties in raising capital.
NeuroOne is a medical technology company focused on improving surgical care for patients with neurological disorders. The company markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. For more information, visit nmtc1.com.
This development matters because it removes a significant overhang on the company's stock and allows management to focus on commercializing its technology and advancing its pipeline. The reverse split, while often viewed negatively by retail investors, was necessary to preserve the Nasdaq listing and could attract institutional investors who may have been restricted from holding penny stocks. The impact on the industry is indirect but positive, as NeuroOne's continued viability supports innovation in neurosurgery and neurostimulation.
Investor relations contact: MZ Group – MZ North America at NMTC@mzgroup.us.
